Star Therapeutics
-
Star Therapeutics Lands $90M to Expand Its Drug Discovery Universe
Startup Star Therapeutics will use the Series B funding to support clinical development of a drug candidate for von Willebrand disease, a bleeding disorder. The capital will also support the formation of new biotech subsidiaries developing antibodies with therapeutic applications in hematology and immunology.
-
Backed by $100M, Star Therapeutics sets out to find constellations of rare disease
Star Therapeutics aims to develop drugs for rare diseases, many of which currently have no FDA-approved treatments. The company forms startups focused on particular areas of biology, and its first one, Electra Therapeutics, is going after a rare autoimmune condition that can become fatal in less than four years.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.